Clinical

Articles

Patients with hematologic malignancies and COVID-19 may experience a survival benefit after receiving convalescent plasma therapy.

Convalescent Plasma Therapy Linked to Potential Survival Benefit for Patients With Hematologic Cancers and COVID-19

Compared with a control therapy, ruxolitinib increased overall response and improved failure-free survival for patients with glucocorticoid-refractory or -dependent chronic graft-versus-host disease.

Ruxolitinib Improved Overall Response in the Treatment of Glucocorticoid-Refractory or -Dependent Chronic GVHD

The ROCK-2–targeting agent belumosudil is now approved by the FDA to treat adult and pediatric patients with chronic graft-versus-host disease after 2 prior lines of therapy.

Belumosudil Granted Full Approval for Treatment of Chronic GVHD by FDA

The level of scientific evidence in National Comprehensive Cancer Network guidelines for malignant hematological conditions haven’t been recently investigated. Herein, investigators describe the distribution of categories of evidence and consensus among the 10 most common hematologic malignancies with regard to recommendations for staging, initial and salvage therapy, and surveillance.

Level of Scientific Evidence Underlying the National Comprehensive Cancer Network Clinical Practice Guidelines for Hematologic Malignancies: Are We Moving Forward?

Julian Adams, PhD, discusses the potential of Omidubicel for patients with hematologic cancers such as lymphomas and leukemias.

Julian Adams, PhD, on Innovating Bone Marrow Transplantation With Omidubicel in Hematologic Malignancies

Videos

Hematologic responses improved for patients treated with daratumumab plus VCd versus VCd alone in the ANDROMEDA trial.

Efstathios Kastritis, MD, on Main Takeaways From Trial Examining Daratumumab Plus VCd to Treat AL Amyloidosis

“These are priceless accomplishments that impact the lives of people.”

Friendly Competition Fosters Progress in Hematologic Malignancies

The expert discussed key details from the phase 3 ANDROMEDA trial presented at the 2021 ASCO Annual Meeting.

Efstathios Kastritis, MD, on Main Findings From the ANDROMEDA Study in Newly Diagnosed AL Amyloidosis

The phase 3 ANDROMEDA trial demonstrated positive efficacy and safety data in the treatment of newly diagnosed light chain amyloidosis.

Efstathios Kastritis, MD, on Implications of Positive Results From the Phase 3 ANDROMEDA Study

TG-1701 elicited promising clinical and pharmacodynamic activity across doses in patients with B-cell malignancies.

Hematology | Topics